PTCT vs. ITCI, GMAB, RDY, VTRS, MRNA, QGEN, ASND, ROIV, RVMD, and BBIO
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.
PTC Therapeutics vs.
PTC Therapeutics (NASDAQ:PTCT) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
Intra-Cellular Therapies has a net margin of -14.07% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Intra-Cellular Therapies' return on equity.
PTC Therapeutics received 55 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. However, 65.74% of users gave Intra-Cellular Therapies an outperform vote while only 62.11% of users gave PTC Therapeutics an outperform vote.
PTC Therapeutics presently has a consensus target price of $63.25, indicating a potential upside of 38.75%. Intra-Cellular Therapies has a consensus target price of $109.70, indicating a potential downside of 16.81%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe PTC Therapeutics is more favorable than Intra-Cellular Therapies.
92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
PTC Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
Intra-Cellular Therapies has lower revenue, but higher earnings than PTC Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, PTC Therapeutics had 13 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 16 mentions for PTC Therapeutics and 3 mentions for Intra-Cellular Therapies. PTC Therapeutics' average media sentiment score of 0.68 beat Intra-Cellular Therapies' score of 0.25 indicating that PTC Therapeutics is being referred to more favorably in the media.
Summary
PTC Therapeutics beats Intra-Cellular Therapies on 12 of the 19 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PTCT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy PTCT Stock Free PTCT Stock Alerts